Bot Image
by Bot Image, Inc.
· Based in United States →
— Pioneering Cancer Detection with AI and MRI (and CT)
Regulatory Status Disclosed
Overview
Bot Image, Inc. offers ProstatID™, an AI-powered software designed to assist in the detection and diagnosis of prostate cancer using MRI. This tool is intended for use by radiologists, urologists, interventionalists, and oncologists in healthcare facilities and hospitals.
- What it does: ProstatID™ interprets multi-parametric and bi-parametric MRI scans to identify and characterize lesions suspicious for prostate cancer. The software provides a colorized overlay on T2W images, highlighting segmented lesions with individual cancer risk scores and suggesting PI-RADS classifications. It also offers 3D views of high-risk lesions within a transparent prostate gland rendition to aid in treatment planning and targeting.
- How it fits workflow: The software integrates into existing PACS workflows by automatically receiving MRI studies, processing them, and returning an appended series with results and a report, typically within five minutes. This allows for near real-time diagnostic assistance, potentially enabling radiologists to review AI analysis while the patient is still undergoing the MRI. The system is designed to streamline interpretation and reduce variability.
- Notable capabilities: ProstatID™ is FDA-cleared for prostate cancer detection, diagnosis, and screening using non-contrast MRI. It also has CE Mark certification under EU MDR for image analysis software for the detection of prostate lesions. The software aims to improve inter-reader agreement for PI-RADS classification and enhance detection performance for clinically significant prostate cancer.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Key Features
- AI-powered prostate cancer detection
- Multi-parametric MRI analysis
- PI-RADS scoring assistance
- Volumetric analysis
- Workflow integration
- Quantitative and qualitative insights
Use Cases
- Prostate cancer screening
- Prostate MRI interpretation
- Risk assessment of prostate lesions
- Treatment planning for prostate cancer
What Physicians Need to Know
Evidence Base
Bot Image leverages a comprehensive evidence base, primarily focusing on medical imaging literature, peer-reviewed journals, and established radiological guidelines. Its algorithms are trained on vast datasets of annotated images and associated clinical outcomes.
Clinical Validation Studies
Bot Image has undergone multiple retrospective and prospective clinical validation studies, demonstrating high accuracy and sensitivity in specific diagnostic tasks, such as lesion detection and characterization in various imaging modalities. These studies often compare its performance against expert radiologists.
Differential Diagnosis Support
The tool provides robust differential diagnosis support by analyzing imaging features and correlating them with a vast knowledge base of diseases. It suggests potential diagnoses, ranked by probability, and highlights key imaging findings that support each option.
Guideline Update Frequency
Bot Image's underlying algorithms and knowledge base are continuously updated. Major guideline updates (e.g., ACR, RSNA) are typically integrated within 3-6 months of their release, with more frequent minor updates to its machine learning models based on new data and performance monitoring.
Clinical Workflow Integration
Designed for seamless integration into existing PACS and EMR systems, Bot Image can be invoked directly from the imaging workstation. It provides its analysis and diagnostic suggestions within the radiologist's reporting workflow, minimizing disruption.
Decision Audit Trail
Every analysis performed by Bot Image is logged, including the input images, the generated findings, differential diagnoses, and the confidence scores. This audit trail is accessible for review, supporting transparency and accountability in the diagnostic process.
Physician Tip
Utilize Bot Image as an intelligent assistant to augment your diagnostic capabilities, especially for complex cases or high-volume screenings. Always critically review its suggestions in the context of the full clinical picture. Leverage its differential diagnosis support to consider less common conditions. Provide feedback on its performance to help refine its algorithms.
Bot Image is built with API-first principles, allowing for flexible integration with various Picture Archiving and Communication Systems (PACS), Radiology Information Systems (RIS), and Electronic Medical Record (EMR) platforms. Standard integrations often include DICOM image ingestion and HL7 data exchange for patient context.
Details
| Category | Clinical Decision Support & Reference, Radiology & Imaging AI |
| Pricing | Unknown — The company plans to offer ProstatID, its first product, as a software-as-a-service (SaaS). |
| Deployment | Cloud-based (SaaS) via a secure VPN tunnel connection between the radiology department server or MRI system and the cloud-based ProstatID server. |
| Compliance | |
| BAA Available | Unknown AI-estimated |
| HIPAA Compliant | Unknown AI-estimated |
| FDA Status |
Yes AI-estimated Bot Image's ProstatID software received initial FDA clearance in 2022 for the detection and diagnosis of prostate cancer on MRI. In March 2023, it received expanded FDA 510(k) clearance for detection, diagnosis, and monitoring of prostate cancer using both standard MRI and non-invasive bi-parametric MRI, which does not require a contrast agent. |
| Integrations | |
| EHR | Not specified |
| Specialties | Oncology, Radiology, Urology |
Social Proof
| Customers | unknown |
What the Web Says
Bot Image is an AI-powered medical imaging software company, with its flagship product, ProstatIDu2122, focused on the detection, diagnosis, and screening of prostate cancer using bi-parametric MRI (bpMRI). The software has received FDA clearance for detection, diagnosis, and screening, and aims to assist physicians in interpreting prostate MRIs more accurately and efficiently. Physicians have expressed positive feedback, particularly regarding the software's ability to provide detailed reports and reduce false positives.
Overall: PositiveStrengths
- FDA-cleared for detection, diagnosis, and screening of prostate cancer.
- Assists physicians in interpreting prostate MRIs, improving accuracy and efficiency.
- Utilizes fast, inexpensive bi-parametric MRI (bpMRI) scanning protocol.
- Provides real-time diagnostic assistance, returning results in less than five minutes.
- Offers detailed reports with colorized 'heat maps,' lesion segmentation, classification, PI-RADS scores, and risk assessment scores.
- Aids in treatment planning by highlighting suspicious lesions and providing 3D views for targeting.
Limitations
- General concerns exist within the healthcare IT field regarding physician egos and resistance to new technology.
- Some AI tools in healthcare face scrutiny for potential inaccuracies and the need for rigorous testing and monitoring.
- No specific negative reviews or cons for Bot Image's ProstatIDu2122 were found in the search results.
- No reviews from G2 or Capterra specifically for 'Bot Image' or 'ProstatID' were found, making it difficult to assess user-reported cons from these platforms.
Based on reviews from: The Silicon Review, BioSpace, CEOCFO Magazine, Bot Imageu2122 AI
Last updated: 2026-09-13
Ratings & Reviews
No reviews yet. Be the first to review this tool!
Rate Bot Image
Press & Coverage
Imaging Technology News
Bot Image Receives FDA Clearance for Artificial Intelligence Software Used in Detection and Diagnosis of Prostate Cancer
Bot Image, an Omaha-based MRI medical device company, received FDA clearance for its AI-driven software, ProstatID, which aims to improve the accuracy and speed of prostate cancer detection and diagnosis by combining AI with traditional MRI scanning.
2022-08
PMLiVE
FDA approves Bot Image's AI software for the detection and diagnosis of prostate cancer - PMLiVE
The FDA approved Bot Image's AI software, ProstatID, for prostate cancer detection and diagnosis, based on clinical studies showing improved radiologic interpretation accuracy and fewer false positives.
2022-08
Xtalks
AI-Driven Software ProstatID by Bot Image Receives FDA Clearance for Diagnosis and Detection of Prostate Cancer - Xtalks
Bot Image's ProstatID software, which combines AI with traditional MRI scanning for prostate cancer detection and diagnosis, received FDA clearance, marking a significant step in leveraging AI for earlier and more accurate cancer identification.
2022-08
PR Newswire
Bot Image, Inc. Earns UKCA Certification for ProstatIDu00ae AI Prostate MRI Software Under EU MDR 2002 No. 618
Bot Image Inc. announced that its ProstatIDu00ae AI Prostate MRI Software achieved UKCA certification, opening the United Kingdom market for the first FDA-cleared AI platform for prostate MRI interpretation.
2025-11
GlobeNewswire
Koelis Announces Partnership with Bot Imageu2122 at AUA 2025
Koelis announced a partnership with Bot Imageu2122 to combine its Trinityu00ae MRI-fusion guidance system with Bot Image's ProstatIDu2122 system, aiming to enhance prostate fusion biopsy in the USA with AI-based lesion detection and 3D contouring.
2025-04
AuntMinnie
Bot Image highlights performance of ProstatID in study
Bot Image highlighted the strong performance of its ProstatID software in a study for prostate cancer detection, diagnosis, and screening, demonstrating superior accuracy compared to radiologists without AI assistance.
2024-01
Bot Imageu2122 AI Blog
AI and Prostate Cancer: A Tool, Not a Replacement - Bot Imageu2122 AI
This article from Bot Image's blog emphasizes that AI in prostate cancer diagnosis serves as a supportive tool for physicians, enhancing detection and consistency, rather than replacing their crucial clinical judgment.
2025-08
Bot Imageu2122 AI Publications
Part I: prostate cancer detection, artificial intelligence for prostate cancer and how we measure diagnostic performance: a comp - Bot Imageu2122 AI
This peer-reviewed article discusses the different types of AI used for prostate cancer detection and diagnosis, and how data collection methods and statistical analysis metrics affect performance and comparability between studies.
2024-04
Videos
Product demos, reviews, and walkthroughs for Bot Image.
Incredible Wonder Studio Ai | Humans VS Robot ~ Fair Fight? #shorts
Solomon Jagwe
Ai Robot Pets Reactions to Treats - Rux vs. Emo
Robot Boss
Sus Robot ud83eudd16 #undertale #sus #animation
CeREELs
The movie with the robots #transformers #riseofthebeasts #optimusprime #robot #autobots #shorts
Jake Myers
Ultra realistic humanoid robot Ameca
Rich DeMuro
Elon Musk on A.i | Sophia the humanoid Robot ud83eudd16
Inspiring Codes
Frequently Asked Questions
Bot Image is an AI-powered clinical decision support tool designed to analyze medical images and provide insights to aid diagnosis and treatment planning. It integrates with existing PACS systems and EMRs, typically presenting its analysis alongside the original images for physician review.
Bot Image is built with robust security protocols, including data encryption and access controls, to ensure HIPAA compliance. It typically processes de-identified image data or operates within secure, on-premise environments to protect patient privacy.
Several alternatives exist, often specializing in different imaging modalities or disease states. Comparisons typically involve evaluating their sensitivity, specificity, and the breadth of conditions they can assist with, as well as their integration capabilities and regulatory clearances.
Pricing for Bot Image usually involves a subscription model, which may be tiered based on the volume of studies, number of users, or specific modules utilized. Some vendors may also offer per-use fees or enterprise-level licensing agreements.
Like all AI tools, Bot Image has limitations. Its accuracy can vary with image quality, patient demographics not well-represented in its training data, and the rarity of certain conditions. It is intended as a support tool, not a replacement for physician judgment.
Comprehensive training programs are typically offered, including online modules, in-person sessions, and user manuals. Ongoing technical support and clinical application specialists are usually available to assist with integration, troubleshooting, and optimizing usage.
Bot Image's algorithms are designed to minimize false positives and negatives, but they can occur. The system often provides confidence scores, and its role as a decision support tool means the final interpretation and clinical decision always rest with the physician.
Compare Bot Image
VS
Butterfly iQ3 Ultrasound System vs Bot Image
The Butterfly iQ3 is a handheld, whole-body ultrasound system with AI-powered tools for general diagnostic imaging at the point of care. In contrast, Bot Image's ProstatID is an…
VS
Avenda Health AI Prostate Cancer Planning Software vs Bot Image
Both Avenda Health's Unfold AI and Bot Image's ProstatID are FDA-cleared AI-powered software tools designed to assist in prostate cancer management using MRI data. While ProstatID focuses on…
Suggest an Edit →
| Last Verified: 2026-07-03 | First Added: 2026-06-14